Changes

Jump to: navigation, search

Chronic myelomonocytic leukemia

No change in size, 16:25, 26 December 2017
m
Text replacement - "#eeee00" to "#91cf61"
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#eeee0091cf61"|Randomized Phase II, <20 pts in subgroup
|[[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#eeee0091cf61"|Randomized Phase II, <20 pts in subgroup
|[[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#eeee0091cf61"|Randomized Phase II, <20 pts in subgroup
|[[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#eeee0091cf61"|Randomized Phase II, <20 pts in subgroup
|[[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#eeee0091cf61"|Randomized Phase II, <20 pts in subgroup
|[[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#eeee0091cf61"|Randomized Phase II, <20 pts in subgroup
|[[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
LookupUsers, editors, emailconfirmed, Administrators
14,670
edits

Navigation menu